InvestorsHub Logo
Followers 468
Posts 26928
Boards Moderated 2
Alias Born 09/11/2006

Re: surf1944 post# 819

Tuesday, 06/26/2012 10:37:10 AM

Tuesday, June 26, 2012 10:37:10 AM

Post# of 2538
9:00AM Dynavax Technologies receives FDA acceptance of HEPLISAV BLA (DVAX) 4.15 : Co announces that the FDA has accepted for review the U.S. Biologics License Application for HEPLISAV, pursuing an indication for immunization against infection caused by all known subtypes of hepatitis B virus in adults 18 through 70 years of age. The co anticipates submitting a European Marketing Authorization Application for HEPLISAV in the third quarter of 2012.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent DVAX News